Chemical

India Glycols reports Rs 358.18 crore revenue & Rs 39.34 crore EBITDA in first post-demerger Q2 results

India Glycols reported a standalone profit after tax (PAT) of Rs 11.24 crore for Q2 FY27

  • By ICN Bureau | November 18, 2026
India Glycols Limited has reported revenue from operations of Rs 358.18 crore and EBITDA of Rs 39.34 crore for the second quarter of FY27, marking its first set of financial results following the demerger of its Spirits & Biofuel and Biopharma businesses into two separate listed entities.
 
The company's unaudited standalone financial results for the quarter and half year ended September 30, 2026, reflect only its continuing operations, comprising Biobased Specialty Materials, Sustainable & Performance Chemicals and Gases.
 
The Spirits & Biofuel Undertaking has been transferred to IGL Spirits Limited, while the Biopharma Undertaking has been demerged into Ennature Bio Pharma Limited. Both entities are now separately listed.
 
India Glycols reported a standalone profit after tax (PAT) of Rs 11.24 crore for Q2 FY27, while quarterly earnings per share (EPS) stood at Rs 1.68.
 
The company's Q2 FY26 comparative figures stood at Rs 2,410.71 crore in revenue, Rs 160.25 crore in EBITDA and Rs 53.94 crore in PAT. However, these figures include the businesses subsequently demerged and are therefore not directly comparable with the current quarter's performance.
 
Sequentially, revenue rose marginally from Rs 354.64 crore in Q1 FY27, while EBITDA and PAT stood at Rs 40.21 crore and Rs 12.35 crore, respectively.
 
For the first half of FY27, India Glycols reported revenue from operations of Rs 712.82 crore, EBITDA of Rs 79.55 crore and PAT of Rs 23.59 crore. Half-yearly EPS stood at Rs 3.52.
 
The corresponding H1 FY26 figures were Rs 4,913.74 crore in revenue, Rs 309.51 crore in EBITDA and Rs 106.79 crore in PAT. These comparative numbers also include the two businesses subsequently demerged and should not be viewed as like-for-like comparisons.
 
Commenting on the results, Rupark Sarswat, Chief Executive Officer, India Glycols Limited, said, “The implementation of the demerger marks an important step in the evolution of India Glycols, enabling a sharper focus on our core business of bio-based specialities and performance chemicals. 
 
"We remain focused on strengthening our capabilities, enhancing operational efficiencies and building on our expertise in the bio-based chemicals space. Going forward, our efforts will be directed towards expanding our business opportunities and creating sustainable long-term value for our stakeholders.”
 
The demerger scheme was approved by the National Company Law Tribunal (NCLT), Allahabad Bench, Prayagraj, through an order dated July 17, 2026. The scheme became effective on September 1, 2026, with April 1, 2026, as the appointed date.
 
Under the arrangement, the Spirits & Biofuel Undertaking was transferred to IGL Spirits Limited and the Biopharma Undertaking to Ennature Bio Pharma Limited as going concerns.
 
The financial results for Q2 FY27 and H1 FY27 consequently exclude the performance of these two businesses. While Q1 FY27 figures have been restated to account for the demerger, the Q2 FY26 and H1 FY26 comparative figures continue to include both undertakings.
 
India Glycols' latest results, therefore, represent the financial performance of its streamlined business following the restructuring, with the company now concentrating on its bio-based speciality materials, sustainable and performance chemicals, and gases operations.

Other Related stories

Startups

Petrochemical

Energy

Digitization